Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 2Plasmacytoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Hematologic Neoplasms 1Esophageal Squamous Cell Carcinoma 1

Interventions

Azacitidine 14venetoclax 10AP 1903 reagent 7Rituximab 6Dexamethasone 6Itraconazole 5Cytarabine 5Bortezomib 5fludarabine 4fedratinib 4belinostat 4Nivolumab 4Lenalidomide 4Imatinib Mesylate 4Daunorubicin 4ARQ531 4pomalidomide 3ibrutinib 3daratumumab 3cc-486 3angiotensin I (1-7) 3Standard of Care 3GSK2110183 3Cyclophosphamide 3zanubrutinib 2tosedostat 2tazemetostat 2tanespimycin 2talquetamab 2tafasitamab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hematologic Neoplasms × CF regimen × Clear all
NCT04632316 2022-06-21

A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

Glycostem Therapeutics BV

Phase 1/2 Unknown
33 enrolled
Other hematologic neoplasm

Leukemia, Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡